Arcus halts Gilead-partnered late-stage trial (RCUS:NYSE)
Summary
Arcus Biosciences (RCUS) stock drops as the company halts a late-stage trial for a lung cancer drug developed with Gilead Sciences (GILD). Read more here.
Description
Arcus Biosciences (RCUS) stock drops as the company halts a late-stage trial for a lung cancer drug developed with Gilead Sciences (GILD). Read more here.
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source